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Abstract 
Acute promyelocytic leukemia (APL) is 
characterized by distinct clinical and biological 
features and by the reciprocal translocation 
t(15;17)(q22;q21) in the majority of patients. The 
translocation generates the fusion of the 
promyelocytic leukemia (PML) gene to the gene for 
retinoic acid receptor alpha (RARA) and these 
patients are responsive to differentiation treatment 
with all-trans retinoic acid (ATRA). Rare cases of 
patients with a morphological diagnosis of APL 
have variant chromosome translocations, which 
fuse RARA gene with partner genes other than 
PML, such as in the variant translocation 
t(5;17)(q35;q21) that fuses the N-terminus of 
nucleophosmin (NPM1) gene at 5q35 to the retinoic 
acid receptor alpha at 17q21. 
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Clinics and pathology 
Disease 
Acute myeloid leukemia (AML) 
Phenotype/cell stem origin 
Acute promyelocytic leukemia (AML-M3 
according to the FAB classification) 
Etiology 
Exceptional; only 7 cases with balanced 
t(5;17)(q35;q12-21) translocation and the 
underlying NPM1/RARA fusion have been 
identified (5 males and 2 females, aged 2.5 to 52 
years).  
There were 2 adult males, aged 29 and 52 years and 
4 patients were pediatric cases, among them 2 were 
12-year-old males and 2 were 2.5 and 9-year-old 
females (Table 1). 
Clinics 
Disseminated intravascular coagulation was present 
at diagnosis in one case; remission obtained with 
chemotherapy and/or ATRA; first relapse at 7 and 5 
months in 2 cases (Corey et al., 1994 ; Hummel et 
al., 1999). The 6-month-old boy described by 
Otsubo et al., presented with cutaneous 
mastocytosis and aleukemic leukemia cutis that 
regressed without any therapy within 6 months. 
Both adult patients also presented with myeloid 
sarcoma, therefore it is likely that it may occur 
frequently in NPM1/RARA associated APL (Nicci 
et., 2005; Kikuma et al.,2015).  
Cytology 
Hypergranular and hypogranular bilobed 
promyelocytes; absence of Auer rods; typical 
microspeckeled pattern with anti-RARa antibodies; 
terminal differentiation of blasts and promyelocytes 
in vitro with ATRA. 
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Table 1.  Reported cases with t(5;17)(q35;q12-21) and confirmed NPM1-RARA fusion. Abbreviations:   M, male; F, female; 
ATRA; all-trans-retinoic acid. 1. Corey et al., 1994 and Redner et al., 1996. 2. Hummel et al., 1999; 3. Grimwade et al., 2000; 4. 
Xu et al., 2001;   5. Nicci et al., 2005; 6. Otsubo et al., 2012; Kikuma et al., 2015. 
 
Prognosis 
The 2.5 years-old child (Corey et al., 1994; Redner 
et al., 1996) was treated with ATRA while in partial 
remission and relapsed shortly after ATRA 
cessation. One of the 12-years old males (Hummel 
et al., 1999) received chemotherapy in induction 
and consolidation and relapsed after 5 months; 
remission was obtained with Ara-C and ATRA 
therapy followed by allogenic BM transplantation, 
but relapsed with therapy refractoriness. The second 
12-years old male who presented with severe DIC 
died of cerebral hemorrhage after 5 days of ATRA 
treatment (Xu et al., 2001). The 9-year-old female 
was treated with ATRA as a part of induction 
therapy and was alive in first CR at 29 months 
(Grimwade et al 2000). The last pediatric patient 
presented with aleukemic leukemia cutis and 
t(5;17)(q35;q12) NPM1/RARA fusion at the age of 
6-month-old (Kanegane et al., 2009; Otsubo et al., 
2012). He showed no sign of leukemia without any 
therapy after 12 months, except for the presence of 
NPM1-RARA transcript in the bone marrow, but 
developed APL at the age of 4 years with complete 
remission to ATRA.  Both adult patients received 
ATRA as part of induction therapy, resulting in 
cytogenetic but not a molecular remission in 1 
patient who relapsed at 22 months after diagnosis 
(Nicci et al., 2005), and in complete hematological 
and molecular remission in the other case (Kikuma 
et al., 2015).  
From these data, the response to ATRA is difficult 
to assess since it was not part of induction treatment 
in some cases and due to the limited number of 
patients. However, patients with NPM1/RARA 
fusion appear to be sensitive to ATRA (Hummel et 
al., 1999; Grimwade et al., 2000; Kikuma et al., 
2015) and cells bearing the t(5;17) terminally 
differentiate in its response (Redner et al., 1996), 
indicating that ATRA can be used to treat 
NPM1/RARA-positive APL patients. It is also 
possible that the presence of the additional/complex 
karyotypic abnormalities may be related to the 
prognosis in this group of patients. 
Cytogenetics 
Additional anomalies 
Sole anomaly in both adult patients (Nicci et al., 
2005; Kikuma et al., 2015) and associated with 
additional anomalies in pediatric patients: del(12p) 
in 1 (Xu et al., 2001), i(21)(q10) in 1 (Otsubo et al., 
2012) and complex anomalies in 2 cases (Hummel 
et al., 1999; Grimwade et al., 2000). 
Variants 
Variant chromosome translocations, which fuse 
RARA with 1 of the partner genes: PML 
(promyelocytic leukemia protein) in 
t(15;17)(q22;q21) that is found in the majority of 
APL patients; ZBTB16 (zinc finger and BTB 
domain containing 16, previously known as PLZF) 
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in t(11;17)(q23;q21) (De Braekeleer et al., 2014); 
NUMA1 (nuclear matrix-mitotic apparatus protein 
1 gene) in t(11;17)(q13;q21) (Wells et al., 1997); 
STAT5B (signal transducer and activator of 
transcription 5 beta) in dup(17)(q21.3q23) (Chen et 
al., 2012); PRKAR1A (protein kinase, cAMP-
dependent, regulatory, type I, alpha) in 
t(17;17)(q21;q24)/del(17)(q21q24) (Catalano et al., 
2007);  FIP1L1 (factor interacting with PAP 1-like 
1) in t(4;17)(q12;q21) (Buijs et al., 2007); NABP1 
(OBFC2A: oligonucleotide/oligosaccharide-binding 
fold containing 2A) in der(2)t(2;17)(q32;q21) (Won 
et al., 2013); TBL1XR1 (TBLR1, GenBank 
KF589333) in a complex t(3;17)(q26;q21), 
t(7;17)(q11.2;q21) (Chen et al., 2014); BCOR 
(BCL6 corepressor gene) in t(X;17)(p11.4;q21) 
(Ichikawa et l., 2015) and the recently described 
new RARA partner IRF2BP2 (interferon regulatory 
factor 2 binding protein 2) in t(1;17)(q42.3; q21) 
(Yin et al., 2015). 
Genes involved and 
proteins 
NPM1 (nucleophosmin) 
Location 
5q35.1 
Protein 
Gene for the nucleolar phosphoprotein 
nucleophosmin; would participate in ribosome 
assembly. 
RARA (Retinoic acid receptor, alpha) 
Location 
17q21.2 
Protein 
Gene for the retinoic acid receptor alpha. Ligand-
dependent transcription factor specifically involved 
in hematopoietic cells differentiation and 
maturation. Receptor for all-trans retinoic acid 
(ATRA) and 9-cis RA. After linking with ATRA, 
RARA binds with RXR (retinoid X receptor 
protein) to the RARE domain (retinoic acid 
response elements), a DNA sequence common to a 
number of genes. The breakpoint lies within the 
second intron of the gene, as in t(15;17) and 
t(11;17) translocations. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
Two reciprocal fusion genes are generated: 5'-
NPM1 + 3'- RARA on der(5) and 5'-RARa + 3'-
NPM on der(17); both fusion genes are transcribed,  
the crucial one is NPM1/RARA; two NPM1/RARA 
chimeric cDNAs are generated, one short and one 
long differing from 129 bp, with corresponding 
transcripts of 2.3 and 2.4 kb (alternatively spliced 
transcripts); in one case, only the short 
NPM1/RARA isoform could be detected; the 5' end 
of NPM1/RARA cDNAs contains the first 442 bp 
of the NPM1 cDNA; the 3' end contains RARA 
sequences of exon 3 through the 3' end of RARA; a 
reciprocal RARA/NPM1 transcript is detected: 
RARA exons 1 and 2 are fused to 3' NPM1 
downstream bp 443. 
Detection 
Nested RT-PCR. 
Fusion protein 
Description 
Two NPM1/RARA proteins, of 563 and 520 amino 
acids, are encoded (MW 62 and 57 kDa); 
NPM1/RARA fusion protein acts as a retinoic acid-
responsive transcriptional activator: increase of 
activity in a concentration dependant manner. 
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